Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC

Table 1 Patient characteristics

	POC Group (n = 82)			C Group (n = 87)			P-value
	n	%	95%CI	n	%	95%CI	P-value
Age (years)							0.93
< 65	42	51.2	(39.9, 62.4)	44	50.6	(39.6, 61.5)
≥ 65	40	48.8	(37.6, 60.1)	43	49.4	(38.5, 60.4)
BMA							0.84
Not used	39	47.6	(36.4, 58.9)	40	46.0	(35.2, 57.0)
Used	43	52.4	(41.1, 63.6)	47	54.0	(43.0, 64.8)
Chemotherapy							0.55
Not used	74	90.2	(81.7, 95.7)	76	87.4	(78.5, 93.5)
Used	8	9.8	(4.3, 18.3)	11	12.6	(6.5, 21.5)
BMI (mg/m²⁾							0.07
< 25	54	65.9	(54.6, 76.0)	66	75.9	(65.5, 84.4)
≥ 25	24	29.3	(19.7, 40.4)	21	24.1	(15.6, 34.5)
Missing	4	4.9	(1.3, 12.0)	0	0.0	(0.0, 4.2)
PgR							0.35
-	12	14.6	(7.8, 24.2)	13	14.9	(8.2, 24.2)
+	65	79.3	(68.9, 87.4)	72	82.8	(73.2, 90.0)
Unknown	2	2.4	(0.3, 8.5)	2	2.3	(0.3, 8.1)
Missing	3	3.7	(0.3, 10.3)	0	0.0	(0. 4.2)
Metastatic site							0.07
Non-visceral	34	41.5	(30.7, 52.9)	28	32.2	(22.6, 43.1)
Visceral	45	54.9	(43.5, 65.9)	59	67.8	(56.9, 77.4)
Missing	3	3.7	(0.8, 10.3)	0	0.0	(0.0, 4.2)
Metastatic type							0.07
De novo	58	70.7	(59.6, 80.3)	72	82.8	(73.2, 90.0)
Metastatic	21	25.6	(16.6, 36.4)	15	17.2	(10.0, 26.8)
Missing	3	3.7	(0.8, 10.3)	0	0.0	(0.0, 4.2)
Endocrine therapy for MBC							0.40
0	13	15.9	(8.7, 25.6)	8	9.2	(4.1, 17.3)
1	17	20.7	(12.6, 31.1)	25	28.7	(19.5, 39.4)
2	23	28.0	(18.7, 39.1)	27	31.0	(21.5, 41.9)
3	29	35.4	(25.1, 46.7)	27	31.0	(21.5, 41.9)
Incidence of oral mucositis within 8 weeks							0.02
No	20	24.4	(15.6, 35.1)	9	10.3	(4.8, 18.7)
Yes	62	75.6	(64.9, 84.4)	78	89.7	(81.3, 95.2)

ISSN: 1471-2407